Systemic therapy for advanced appendiceal adenocarcinoma: An analysis from the NCCN oncology outcomes database for colorectal cancer

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 12, Issue 8, 2014, Pages 1123-1130

  Tejani, Mohamedtaki A ^a   Veer, Anna Ter ^b   Milne, Dana ^c   Ottesen, Rebecca ^b   Bekaii Saab, Tanios ^d   Benson III, Al B ^e   Schrag, Deborah ^c   Shibata, Stephen ^b   Skibber, John ^f   Weiser, Martin ^g   Wilkinson, Neal ^h   Cohen, Steven J ^a  

^a FOX CHASE CANCER CENTER   (United States)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d OHIO STATE UNIVERSITY   (United States)

^e NORTHWESTERN UNIVERSITY   (United States)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^g MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^h ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; FLUOROPYRIMIDINE; FLUOROURACIL; IRINOTECAN; OXALIPLATIN; ANTINEOPLASTIC AGENT; FOLINIC ACID; PLATINUM COMPLEX;

ADENOCARCINOMA; ADULT; AGED; APPENDIX CANCER; APPENDIX CARCINOMA; ARTICLE; COLORECTAL CANCER; DATA BASE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; SYSTEMIC THERAPY; APPENDICEAL NEOPLASMS; COLORECTAL NEOPLASMS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; MIDDLE AGED; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; UNITED STATES;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APPENDICEAL NEOPLASMS; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; KAPLAN-MEIER ESTIMATE; LEUCOVORIN; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; TREATMENT OUTCOME; UNITED STATES;

EID: 84906234286     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2014.0109     Document Type: Article

References (22)

1. Siegel R, Naishadham D, Jemal A. Cancer Statistics, 2012. CA Cancer J Clin 2012;62:10-29.
2. Connor S, Hanna G, Frizelle F. Appendiceal tumors: retrospective clinicopathologic analysis of appendiceal tumors from 7,970 appendectomies. Dis Colon Rectum 1998;41:75-80. (Pubitemid 28044879)
3. McCusker M, Cote T, Clegg L, Sobin LH. Primary malignant neoplasms of the appendix: a population-based study from the Surveillance, Epidemiology, and End-Results program 1973-1998. Cancer 2002;94:3307-3312. (Pubitemid 34670516)
4. Smith J, Kemeny N, Caldwell C, et al. Pseudomyxoma peritonei of appendiceal origin. The Memorial Sloan-Kettering Cancer Center experience. Cancer 1992;70:396-401.
5. Gough D, Donohue J, Schutt A, et al. Pseudomyxoma peritonei: Long-term patient survival with an aggressive regional approach. Ann Surg 1994;219:112-119. (Pubitemid 24064067)
6. Baratti D, Kusamura S, Nonaka D, et al. Pseudomyxoma peritonei: clinical, pathological and biological prognostic factors in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol 2008;15:526-534.
7. Shapiro J, Chase J, Wolff R, et al. Modern systemic chemotherapy in surgically unresectable neoplasms of appendiceal origin. Cancer 2010;116:316-322.
8. Lieu CH, Lambert LA, Wolff RA, et al. Systemic chemotherapy and surgical cytoreduction for poorly differentiated and signet ring cell adenocarcinomas of the appendix. Ann Oncol 2012;23:652-658.
9. Farquharson AL, Pranesh N, Witham G, et al. A phase II study evaluating the use of concurrent mitomycin C and capecitabine in patients with advanced unresectable pseudomyxoma peritonei. Br J Cancer 2008;99:591-596.
10. Song X, Zhao Z, Barber B, et al. Treatment patterns and metastasectomy among mCRC patients receiving chemotherapy and biologics. Curr Med Res Opin 2011;27:123-130.
11. Love N, Haller DG. Patterns of care in medical oncology: management of cancer of the colon and rectum in the adjuvant and metastatic settings. Available at www.researchtopractice.com. 2008;5:1.
12. Benson AB III, Venook AP, Bekaii-Saab T, et al. NCCN Clinical Practice Guidelines in Oncology: Colon Cancer. Version 3, 2014. Available at: NCCN.org. Accessed June 13, 2014.
13. Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008;26:2013-2019.
14. Nitecki SS, Wolff BG, Schlinkert R, et al. The natural history of surgically treated primary adenocarcinoma of the appendix. Ann Surg 1994;219:51-60.
15. Cortina R, McCormick K, Kolm P, et al. Management and prognosis of adenocarcinoma of the appendix. Dis Colon Rectum 1995;38:848.
16. Kabbani W, Houlihan PS, Luthra R, et al. Mucinous and nonmucinous appendiceal adenocarcinomas: different clinicopathologic features but similar genetic alterations. Mod Pathol 2002;15:599.
17. Sugarbaker P, Zhu B, Sese G, et al. Peritoneal carcinomatosis from appendiceal cancer: results in 69 patients treated by cytoreductive surgery and intraperitoneal chemotherapy. Dis Colon Rectum 1993;36:233.
18. Sugarbaker P, Chang D. Results of treatment of 385 patients with peritoneal surface spread of appendiceal malignancy. Ann Surg Oncol 1999;6:727-731. (Pubitemid 30013648)
19. Niland JC. NCCN outcomes research database: data collection via the Internet. Oncology (Williston Park) 2000;14:100-103.
20. Rajput A, Romanus D, Weiser MR, et al. Meeting the 12 lymph node benchmark in colon cancer. J Surg Oncol 2010;102:3-9.
21. Sanoff HK, Carpenter WR, Martin CF, et al. Comparative effectiveness of oxaliplatin vs. non-oxaliplatin-containing adjuvant chemotherapy for stage III colon cancer. J Natl Cancer Inst 2012;104:211-227.
22. LaCasce AS, Vandergrift JL, Rodriguez MA, et al. Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL Database. Blood 2012;119:2093-2099.